Quetiapine vs Trazodone for Postpartum Depression
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the drugs Quetiapine and Trazodone for postpartum depression?
There is no direct evidence from the provided research articles supporting the effectiveness of Quetiapine or Trazodone specifically for postpartum depression. However, Quetiapine has been studied for preventing mood episodes in women with bipolar disorder during the postpartum period, suggesting it may have some mood-stabilizing effects.12345
Is quetiapine safe for use during breastfeeding?
How does the drug Quetiapine differ from other treatments for postpartum depression?
Quetiapine is unique because it is an atypical antipsychotic that is also used to treat bipolar depression, offering potential benefits for postpartum depression by improving depressive and anxiety symptoms. Unlike some other antidepressants, it is not associated with an increased risk of treatment-emergent mania, which may make it a suitable option for postpartum depression.123910
What is the purpose of this trial?
Postpartum depression is a serious disorder that affects approximately 17% of women who have recently given birth. Untreated postpartum depression can negatively affect the mother, the infant, and the family. Lack of sleep is common after delivery and can trigger or worsen depression in some women. Trazodone is used for sleeplessness and depression, but it has not been studied for postpartum depression. There is preliminary evidence that quetiapine, another drug used for depression and sleeplessness, may be effective for postpartum depression. We are planning a study to compare the effectiveness and side effects of quetiapine and trazodone in women with postpartum depression. The results of this study will help us carry out larger studies comparing these drugs with a placebo (a sugar pill) in postpartum depression. We expect the results of our study will improve the mental health of mothers and the well-being of their babies and make it easier for healthcare staff to select the right drug for women with postpartum depression.
Eligibility Criteria
This trial is for women who have recently given birth and are experiencing postpartum depression. Participants should not have been treated yet for their condition. The study aims to help those struggling with sleeplessness and depressive symptoms after delivery.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants are randomized to receive either trazodone or quetiapine with dose adjustments over 8 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment completion
Treatment Details
Interventions
- Quetiapine
- Trazodone
Quetiapine is already approved in United States, European Union for the following indications:
- Bipolar disorder (depressive and manic episodes)
- Schizophrenia
- Major depressive disorder
- Schizophrenia
- Bipolar disorder (manic episodes)
- Major depressive episodes in bipolar disorder
Find a Clinic Near You
Who Is Running the Clinical Trial?
Lawson Health Research Institute
Lead Sponsor
London Health Sciences Centre OR Lawson Research Institute of St. Joseph's
Lead Sponsor
London Health Sciences Centre Research Institute and Lawson Research Institute of St. Joseph's
Lead Sponsor
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Lead Sponsor